Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F16%3A00065502" target="_blank" >RIV/00159816:_____/16:00065502 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/16:00065502 RIV/00843989:_____/16:E0105669 RIV/44555601:13450/16:43887918

Result on the web

<a href="http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024823" target="_blank" >http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024823</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024823" target="_blank" >10.1161/CIRCULATIONAHA.116.024823</a>

Result language

angličtina

Original language name

Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

Original language description

BACKGROUND: No randomized "head-to-head" comparison of the efficacy and safety of ticagrelor vs. prasugrel has been published in the seven years since the higher efficacy of these newer P2Y12 inhibitors were first demonstrated relative to clopidogrel. The study was prematurely terminated for futility. The occurrence of the primary endpoint did not differ between groups receiving prasugrel and ticagrelor (4.0% and 4.1%, respectively; OR (95% CI) 0.98 (0.55; 1.73); P=0.939). No significant difference was found in any of the components of the primary endpoint. The occurrence of key secondary end-point within 30 days, composed of cardiovascular death, non-fatal MI, or stroke did not show any significant difference between prasugrel and ticagrelor (2.7% and 2.5%, respectively; OR (95% CI) 1.06 (0.53; 2.15); P=0.864). CONCLUSION: This head-to-head comparison of prasugrel and ticagrelor does not support the hypothesis that one is more effective or safer than the other in preventing ischemic and bleeding events in the acute phase of myocardial infarction treated with primary PCI strategy. The observed rates of major outcomes were similar, although with broad confidence intervals around the estimates. These interesting observations need to be confirmed in a larger trial.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FA - Cardiovascular diseases including cardio-surgery

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Circulation

ISSN

0009-7322

e-ISSN

—

Volume of the periodical

134

Issue of the periodical within the volume

21

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

1603-1612

UT code for WoS article

000388466500009

EID of the result in the Scopus database

—